Research shows that rapid antigen tests are performing as well at detecting the most recent dominant variants as they did with the earliest strains in the COVID-19 pandemic.
Academic rigor, journalistic flair
Articles on Virus variants
Displaying all articles
Many questions remain about next steps for US vaccine policy. But the FDA advisory panel’s hearty endorsement of a single-composition COVID-19 vaccine represents a pivotal step.
The FDA’s authorization of COVID-19 shots for children ages 6 months to 4 years will bring relief for millions of parents. Pending CDC endorsement, shots for this group will be available within days.
A new generation of vaccines and boosters against SARS-CoV-2 may take a page from the anti-influenza playbook, with shots periodically tailored to target the most commonly circulating virus strains.
Moderna will ask the FDA to allow emergency use for its vaccine in children as young as 6 months, a step many parents have been anticipating.
It’s too early to say whether the newly identified omicron variant is going to overtake delta. But particular mutations in the new strain have researchers deeply concerned.
Two different respiratory viruses were found to swap proteins when they infected the same cell.
Top contributors
-
Associate Professor of Pediatrics, University of Virginia
-
Professor and Department Chair of Infectious Diseases and Microbiology, University of Pittsburgh
-
Instructor of Human Immunology, Emory University
-
Professor of Pediatrics, University of Pittsburgh
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Associate Professor of Pediatrics and Director of Pediatric Residency Program, Morehouse School of Medicine
-
Postdoctoral Fellow in Epidemiology, University of North Carolina at Chapel Hill
-
Assistant Professor of Pediatrics, Emory University
-
Assistant Professor of Medicine, UMass Chan Medical School
-
Lecturer in Virology, Queen's University Belfast
-
Associate Professor of Molecular Medicine, UMass Chan Medical School
